SFRP2 and dysplasia: The ENDCAP-C trial, a multicenter study to assess the role of molecular markers in improving the detection of dysplasia, identified the methylation of a five-marker panel (SFRP2, SFRP4, WIF1, APC1A, APC2) that accurately detected ulcerative colitis associated dysplasia.